Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Biotech
BMS' CELMoD drug improves myeloma PFS in phase 3
The Cereblon E3 ligase modulator was tied to a statistically significant improvement in progression-free survival among multiple myeloma patients.
James Waldron
Mar 9, 2026 11:08am
Quest launches residual disease blood test for multiple myeloma
Feb 3, 2026 6:15am
FDA outlines draft policy on MRD for accelerated approval
Jan 21, 2026 2:55pm
Exicure scores in phase 2 multiple myeloma program
Dec 9, 2025 10:15am
Fierce Pharma
ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma
Dec 9, 2025 7:30am
ASH: Anito-cel strengthens potential as Kite preps for launch
Dec 7, 2025 11:52am
